Cryoport, Inc.
NASDAQ•CYRX
CEO: Mr. Jerrell W. Shelton
板块: Industrials
行业: Integrated Freight & Logistics
上市日期: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
联系方式
市值
$418.58M
市盈率 (TTM)
5.6
38
股息率
--
52周最高
$11.45
52周最低
$4.63
52周范围
排名63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 1.8 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q4 2025 数据
营业收入
$45.45M+0.00%
近4季度走势
每股收益
-$0.27+0.00%
近4季度走势
自由现金流
-$15.73M+0.00%
近4季度走势
2025 Annual 财报亮点
核心亮点
Total Revenue Growth Total revenue reached $176.2M, marking a 12.4% increase. Life Sciences Services revenue grew 17.6% to $96.5M.
Profitability Reversal Achieved Net Income of $78.3M in 2025, a significant shift from Net Loss of ($114.8M) reported in 2024.
Strategic Divestiture Gain Completed CRYOPDP divestiture for $133.0M in Q2 2025, resulting in a $117.0M gain recognized in operations.
CGT Market Support Supported 760 clinical trials globally; 20 commercial therapies generated $33.4M revenue, increasing 28.6%.
关注风险
Component Supply Dependency Dependence on third-party component availability; delays or increased procurement costs could adversely affect financial performance.
Global Regulatory Exposure Operations face risks from changing international trade policies, currency fluctuations, and complex governmental regulations.
Product Liability Exposure Risk of liability claims exceeding insurance coverage, particularly concerning products used in human reproductive medicine.
Cybersecurity System Failure Critical information systems face constant cyberattacks; system compromise could materially harm operations and reputation.
前瞻展望
Digital Strategy Enhancement Established Enterprise Technology Group (ETG) to drive digital initiatives, integrating AI and advanced analytics across platforms.
Infrastructure Expansion Plans Opened Paris Global Supply Chain Center in 2025; planning another center in Santa Ana, California, late 2026.
MVE System Connectivity Plans to introduce MVE CryoVerse Ecosystem in 2026 for real-time monitoring and enhanced compliance visibility.
Future Capital Requirements Management recognizes potential need for additional equity or debt capital until sustained profitability is achieved.
同行对比
营业收入 (TTM)
$2.50B
$1.87B
$1.83B
毛利率 (最新季度)
89.1%
59.8%
48.4%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| FWRD | $746.21M | -6.9 | -77.1% | 91.5% |
| TWI | $568.53M | -8.9 | -11.6% | 42.5% |
| EBF | $543.61M | 12.9 | 14.1% | 2.9% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
3.5%
温和增长
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
25%
现金流需要关注
深度研究
下次财报:2026年4月30日
每股收益:-$0.22
|营业收入:$44.87M
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据